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Summary
Introduction. — We estimated the cost-effectiveness of atorvastatin in the primary prevention
of cardiovascular events in patients with type 2 diabetes using data from the Collaborative
AtoRvastatin Diabetes Study (CARDS).
Methods. — A total of 2838 patients aged 40—75 years with type 2 diabetes and no documented
history of cardiovascular disease and without elevated low-density-lipoprotein cholesterol were
recruited in the UK and in Ireland. Patients were randomly allocated to atorvastatin 10mg daily
(n = 1428) or placebo (n = 1410) and were followed up for a median of 3.9 years. Direct treatment
costs and effectiveness were analysed to provide estimates of cost per event avoided and cost
per life-year gained over the trial period and over a patient’s lifetime.
Results. — The incremental cost-effectiveness ratio over the trial period was estimated to be
D 3862 per clinical event avoided. Over the patient’s lifetime, the incremental cost per life-
year gained was D 2506 when considering cardiovascular deaths, and D 1418 per year when
considering all-cause death.
Conclusions. — Primary prevention of cardiovascular disease with atorvastatin is cost-effective
in patients with type 2 diabetes, with the incremental cost-effectiveness ratio for this inter-
vention falling within the current acceptance threshold.
© 2008 Published by Elsevier Masson SAS.
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Résumé
Introduction. — Nous avons estimé le ratio coût—efﬁcacité de l’atorvastatine dans la prévention
primaire des événements cardiovasculaires chez les patients diabétiques de type 2 au moyen
des données de l’étude CARDS.
Méthodes. — Au total, 2838 patients, âgés de 40 à 75 ans avec un diabète de type 2, sans
antécédent cardiovasculaire, ni élévation du LDL cholestérol ont été recrutés dans des cen-
tres britanniques et irlandais. Après tirage au sort, ils ont été traités par 10mg quotidien
d’atorvastatine (n = 1428) ou un placebo (n = 1410). La durée médiane de suivi de ces patients
était de 3,9 ans. Les coûts directs et l’efﬁcacité ont été analysés pour calculer des coûts par
événement évité et des coûts par année de vie gagnée sur la période de l’essai et sur la vie
entière des patients.
Résultats. — Sur la période de l’essai, le ratio coût—efﬁcacité incrémental a été estimé à 3862D
par événement évité tel que déﬁni dans le protocole de CARDS. Sur la vie entière, le coût par
année de vie gagnée était estimé à 2506D en considérant les décès d’origine cardiovasculaire
et à 1418D en considérant tous les décès.
Conclusion. — La prévention primaire des événements cardiovasculaires par atorvastatine chez
les patients diabétiques de type 2 est une stratégie coût—efﬁcace avec un ratio coût—efﬁcacité
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ntroduction
iabetic patients are at high risk of cardiovascular morbidity
nd mortality [1]. Since the introduction of statins 20 years
go, their indications have broadened with the emergence
f data from numerous large randomized clinical trials.
ow their approved indications include treatment of ele-
ated low-density-lipoprotein (LDL) cholesterol, secondary
revention of cardiac events, and primary prevention of car-
iac events in large subgroups of the population, including
hose with diabetes and at least one additional risk fac-
or and without elevated LDL cholesterol. Atorvastatin was
ecently approved for the latter indication in France, based
n the results of the Collaborative AtoRvastatin Diabetes
tudy (CARDS) [2—4]. This clinical trial was performed under
he aegis of the UK Department of Health and was coordi-
ated by University College London. The trial was designed
o demonstrate the efﬁcacy of atorvastatin in the primary
revention of cardiac events in patients presenting with dia-
etes and without elevated LDL cholesterol.
While there is no question as to the efﬁcacy of ator-
astatin in this group, it is important to evaluate its
ost-effectiveness because of the large number of indi-
iduals who could beneﬁt from the product. The French
ransparency Commission estimated this target population
o be approximately 600 000 in France [5]. The cost-
ffectiveness of atorvastatin has already been studied in
pain [6] and in the United Kingdom [7], but healthcare
ystems and medical expenses vary widely between coun-
ries. Therefore, the objective of the present study was to
stimate its cost-effectiveness in the primary prevention
f cardiac events in a French diabetic population without
levated LDL cholesterol.ethods
his study is based largely on data from the CARDS clin-
cal trial, which has been described in detail elsewhere
2—4]. In brief, a population of UK patients was randomly
D
p
[
fnsidéré comme acceptable.
sson SAS.
llocated to placebo or atorvastatin (10mg daily). Patients
ere eligible for inclusion if they were diabetic, had no his-
ory of cardiac events, had an LDL cholesterol level lower
han 4.14mmol/L, and had at least one associated risk
actor (retinopathy, albuminuria, current smoking or hyper-
ension). The median duration of follow-up was 3.9 years in
oth groups. The risk reduction of cardiovascular events was
stimated at 37% (95% conﬁdence interval 17—52; P < 0.001)
or atorvastatin, and treatment of 1000 patients could avoid
7major events each year. Treatment was associated with a
ortality reduction of 27% (P = 0.059) during the follow-up
eriod. No signiﬁcant side-effects were observed in either
roup and the trial was stopped prematurely because of the
igniﬁcance of efﬁcacy in the second planned intermediary
nalysis.
The present cost-effectiveness study was carried out
ccording to French guidelines [8,9]. The primary endpoints
ere the number of clinical events observed during the trial
nd the life expectancy of patients extrapolated to the life-
ime of a similar population, comparing atorvastatin 10mg
aily to usual care without systematic atorvastatin treat-
ent.
The number of cardiac events was extracted from the
ain article [4] and the clinical report. Owing to statistical
onsiderations, the ﬁrst event of one type was considered
er patient in the article, which could lead to an underesti-
ation of the economic difference between groups because
atients with a ﬁrst event are more likely to present with a
econd.
Life-expectancy estimates were calculated using the
EALE method [10]. This approach allows us to estimate
he life expectancy of a particular population, taking into
ccount the decrease in life expectancy of diabetic patients
ompared with that of the general population, and was
ased on data from Gu et al. [11]. In the UK Prospective
iabetes Study (UKPDS), the life expectancy of diabetic
atients with a mean age of 54 was approximately 20 years
12,13].
The following calculations were performed as
ollows:
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Table 1 Standard costs of cardiac events observed during CARDS inﬂated to 2007 prices.
Cardiac event Cost of hospitalization
(D 2007)
Cost post-hospitalization (D )
1st year
Total
cost (D )
Non-fatal myocardial infarction 5014 11,098 16,112
Fatal myocardial infarction 4709 — 4709
Percutaneous coronary intervention 12,403 — 12,403
Stroke 6057 10,287 16,344
Fatal stroke 7167 — 7167
t
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tAngina 4404
Non-fatal cardiac arrest 9890
Sudden death 7350
• yearly mortality rate according to age and sex (ASR) cal-
culated from French life-expectancy tables [14] (LEASR)
with ASR = 1/LEASR;
• mortality rate speciﬁc to diabetes (D);
• calculation of the speciﬁc life expectancy of the diabetic
population (PSLE) PSLE = 1/(ASR +D).
where ASR = age—sex ratio, LE = life expectancy, and
PSLE = patient-speciﬁc life expectancy.
The characteristics of the CARDS population were
included, namely median age 63 years, seven-year history
of diabetes, 32% women, and a follow-up duration of four
years. The ﬁnal estimate was applied to deaths avoided to
estimate the total number of additional life years of patients
in the atorvastatin group. The population of interest corre-
sponded to the one included in the trial as well as the time
horizon (3.9 years). The economic perspective concerned
the French Sickness Fund because all patients in France who
present with diabetes are fully reimbursed as their condition
is categorized as chronic (affection de longue durée : long
term disease) [15].
Considered costs were those of the statin — investigators
could prescribe statins according to their clinical judge-
ment — and the costs of treatment for cardiac events.
Neither the cost of follow-up nor the indirect costs were
t
e
w
l
Figure 1. Use of statins according to treatment group and year of foll3003 7407
— 9890
— 7350
aken into account because statin management does not add
igh costs to the current management of diabetic patients
nd no relevant information was available for indirect
osts.
The information available from CARDS on resources used
as valued using French standard costs. The unit costs of
reating cardiac events in diabetic patients were those pub-
ished recently [16] based on an analysis of the national
ospital discharge database (programme médicalisé des sys-
èmes d’informations [PMSI]) and the published literature.
hese estimates were inﬂated using the healthcare service
rice index [17], and are presented in Table 1.
The costs of statin treatment were based on their use in
he CARDS study in both groups. Costs were calculated using
007 ofﬁcial tariffs, and for statins other than atorvastatin
ere based on the market share of the different dosages
nd types available (including generic and brand name prod-
cts). The rates of statin use according to year of follow-up
n CARDS is shown in Fig. 1. No discount rate was applied
o these costs because of the relatively short duration of
he study and mainly because of the lack of information on
vent chronology.
Incremental cost-effectiveness ratios were calculated
ith the criteria deﬁned above (all cardiac events and per
ife-year gained) and using the calculated costs. Sensitivity
ow-up in the CARDS study.
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Table 2 Number of events observed during CARDS [4 and data on ﬁle].
Atorvastatin (n = 1428) Placebo (n = 1410) Difference
First event n (%) n (%) — (%)
Fatal myocardial infarction 8 0.56 20 1.42 −12 −0.86
Other fatal acute coronary event 10 0.70 4 0.28 +6 0.42
Non fatal myocardial infarction 25 1.75 41 2.91 −16 −1.16
Unstable angina 7 0.49 9 0.64 −2 −0.15
PCI 12 0.84 18 1.28 −6 −0.44
Fatal stroke 1 0.07 5 0.35 −4 −0.28
Non fatal stroke 20 1.40 30 2.13 −10 −0.73
Total ﬁrst events 83 5.81 127 9.01 −44 −3.19
Other events
Non fatal myocardial infarction 8 11 −3
Unstable angina 3 1 2
PCI 12 18 −6
Stroke — 8 −8
Total other events 23 38 −15
Total events 106 7.42 165 11.70 −59 −4.28
Cardiovascular death 25 1.75 37 2.62 −12 −0.87
All-cause death 61 4.27 82 5.82 −21 −1.54
n.
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dMI, myocardial Infarction; PCI, percutaneous coronary interventio
nalyses were performed by calculating cost-efﬁcacy ratios
or ﬁrst events only (based on the results of the article) and
or life-year gained in the clinical trial period (two years lost
er fatal event, on average).
esults
linical endpoints
he number of cardiac events observed during the CARDS
rial is shown in Table 2. Of the 1428 patients in the ator-
astatin group, 83 presented at least one cardiac event as
eﬁned by the protocol, compared with 127 of 1410 patients
n the placebo group. The risk reduction was calculated at
7% (P < 0.001). Separately assessed, atorvastatin reduced
he risk of acute coronary heart disease by 36%, coronary
a
a
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Table 3 Costs per patient of cardiac events and statins accor
Atorvastatin
Cost of statin (D ) 839
Cost per event 26
Fatal myocardial infarction 26
Non fatal myocardial infarction 372
Other coronary event 69
Unstable angina 52
Fatal stroke 5
Non fatal stroke 229
Revascularization 208
Event cost 962
Total cost 1801evascularization by 31%, and stroke by 48%. Atorvastatin
lso reduced mortality by 27% (P = 0.059). Secondary events
ere less frequent in the atorvastatin group (n = 23) than in
he placebo group (n = 38).
Using the DEALE method, diabetic patients with a mean
ge of 67 years (at the end of CARDS follow-up) had an
verage life expectancy of 7.55 years.
osts
verage costs per patient of statins and management of car-
iac events are presented in Table 3.The extra cost of the atorvastatin strategy was estimated
t D 165 per patient. This extra cost was due mainly to the
dditional cost of statins (+D 727), but was offset partly by
he lower costs associated with treatment of cardiac events
—D 562) in the atorvastatin group.
ding to treatment group.
Usual care Difference
112 727
67 −40
67 −40
594 −222
28 41
53 −1
25 −20
440 −212
317 −108
1524 −562
1636 165
Atorvastatin in the prevention of cardiovascular events in diabetic patients 331
Table 4 Cost-effectiveness ratios of atorvastatin versus usual care according to endpoint criteria.
Extra costs of atorvastatin
strategy per patient (D )
Events avoided
per patient
Cost per event
avoided (D )
Cost per life-year gained
(7.5 years gained per
death avoided) (D )
All cardiac events 165 0.0427 3862 —
0087
0154
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oCardiovascular death 0.
All-cause death 0.
Cost-effectiveness
The calculated cost-effectiveness ratios are presented in
Table 4. The incremental cost-efﬁcacy ratios of atorvastatin
were estimated at D 3862 per cardiac event avoided (D 165
divided by 4.27% of cardiac events avoided), at D 18 920 per
cardiovascular death avoided (D 165 divided by 0.87%), and
at D 10 704 per death avoided (D 165 divided by 1.54%). Based
on an average beneﬁt of 7.5 years per avoided death, costs
per life gained were, respectively, D 2506 for cardiovascular
death and D 1418 for all-cause death.
Sensitivity analyses
The results of the sensitivity analyses are given in Table 5.
The extra cost of the atorvastatin strategy when taking into
account only the ﬁrst events was D 337 per patient due
to a lower number of events avoided. Costs per life-year
gained were higher when considering only the lifetime ben-
eﬁt within the clinical trial period.
Discussion
The results from the CARDS study [2—4] demonstrated the
efﬁcacy of atorvastatin in the primary prevention of car-
diovascular events in diabetic patients. The results of our
study show that atorvastatin appears to be cost-effective in
the French setting.
Our study is subject to certain limitations. First, we
applied standard costs to clinical events rather than valuing
the direct resources used in the CARDS study. The lat-
ter approach was used in the UK economic study [7], as
the researchers used data that was relevant for their own
healthcare system. Nevertheless, French hospital costs are
driven by the diagnosis-related group system, and the use
of hospital daily cost does not provide the best estimate
for cardiovascular-event costs. Our approach of using stan-
dard costs based on national estimates avoided the main
problem associated with estimated costs based on data col-
o
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Table 5 Sensitivity analyses.
Extra costs of atorvastatin
strategy per patient (D )
Events av
per patie
All cardiac events 337 0.0319
Cardiovascular death 0.0087
All-cause [ok?] death 0.015418 920 2506
10 704 1418
ected, i.e. the inclusion of outliers, which could have biased
he results. Fernandez de Bobadilla et al. [6], in a Spanish
ost-effectiveness study, used a design similar to ours.
The second limitation is that the CARDS study was
topped prematurely and extrapolation of time was neces-
ary to estimate the efﬁcacy in terms of life expectancy.
e chose to estimate the cost-efﬁcacy ratios on the basis of
esources consumed during the clinical trial, whereas British
esearches extrapolated both lifetime treatment with ator-
astatin and efﬁcacy. Our main concern about this design
s that, as shown in Fig. 1, a large proportion of patients
n the placebo arm will use statins and this proportion
ould increase dramatically over time. As a consequence,
e preferred to use costs and efﬁcacy based on the trial
eriod.
The British study [7] was performed from the perspective
f a unique healthcare purchaser — the National Health Ser-
ice — and included only healthcare costs. They authors used
wo time horizons, the period of the trial and the patient’s
ifetime. Time extrapolation was based on the assumption
hat patients on atorvastatin would be treated until they
ied, and that the cumulative survival difference observed
n CARDS would continue over time. The authors calcu-
ated three endpoints: cardiac events and strokes (primary
ndpoints), any cardiovascular event (including other acute
oronary heart disease events, transient ischaemic attack,
eripheral vascular diseases, etc), and any adverse events
including all-cause death). Costs were based on resource
onsumption during the trial period (medications, visits,
xaminations, and hospitalizations) and standard costs were
pplied. Results that are strictly comparable with our study
stimates were as follows: (1) cost per event avoided for
he ﬁrst cardiac event, with our estimate of D 10 555 to be
ompared with £7608 (D 10 879 using their exchange rate
f D 1.43 per £); and (2) cost per life-year gained, with
ur estimate of D 2506 to be compared with £2755 (D 3939)
er life-year gained in the UK study. The difference can
e explained by the additional cost of atorvastatin in the
reated group and a longer life-expectancy due to this treat-
ent.
oided
nt
Cost per event
avoided (D )
Cost per life-year
gained (2 years gained
per death avoided) (D )
10 555 —
38 609 19 305
21 842 10 921
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The Spanish study [6] was based on a model that mim-
cked the clinical trial results and extrapolated the life
xpectancy of patients according to the occurrence of an
vent (or not) with the published results. Standard costs of
vents were then applied. The authors found a cost per life-
ear gained of D 5886. This higher estimate is due mainly to
he higher cost (+50%) of atorvastatin in Spain at the time
he study was conducted.
The results of these three studies, despite their differ-
nt study designs, offer similar ﬁndings to our own: that
torvastatin is cost-effective and should be recommended
n this population. In conclusion, therefore, primary pre-
ention of cardiovascular disease with atorvastatin is a
ost-effective intervention in French patients with type
diabetes, with the incremental cost-effectiveness ratio
or this intervention falling within the current acceptance
hreshold, irrespective of the assumptions underlying the
alculations.
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